Literature DB >> 6311774

"Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis.

G Abbruzzese, C Gandolfo, C Loeb.   

Abstract

Two groups of 30 multiple sclerosis (MS) patients were randomly treated with corticotrophin (ACTH) and "bolus" 6-methylprednisolone (B/6-MP) to compare the effectiveness of the two treatments. Both ACTH and B/6-MP showed a similar effect, improving acute neurological deficits of MS patients without modifying the long term course of the disease. B/6-MP, showing prompt effectiveness and lack of side effects, may be regarded as a useful alternative to conventional treatment of MS.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311774     DOI: 10.1007/bf02043900

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  15 in total

1.  FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1965-07       Impact factor: 9.910

Review 2.  A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis.

Authors:  G W Ellison; L W Myers
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

3.  "Pulse" methylprednisolone therapy in the treatment of severe glomerulonephritis.

Authors:  B R Cole; J T Brocklebank; R A Kienstra; J M Kissane; A M Robson
Journal:  J Pediatr       Date:  1976-02       Impact factor: 4.406

4.  High-dosage intravenously administered methylprednisolone in renal transplantation. A preliminary report.

Authors:  J E Woods; C F Anderson; J H DeWeerd; W J Johnson; J V Donadio; F J Leary; P P Frohnert
Journal:  JAMA       Date:  1973-02-19       Impact factor: 56.272

5.  Long-term treatment of multiple sclerosis with corticotrophin.

Authors:  J H Millar; C J Vas; M J Noronha; L A Liversedge; M D Rawson
Journal:  Lancet       Date:  1967-08-26       Impact factor: 79.321

6.  Intravenous pulse methylprednisolone therapy of acute crescentic rapidly progressive glomerulonephritis.

Authors:  W K Bolton; W G Couser
Journal:  Am J Med       Date:  1979-03       Impact factor: 4.965

Review 7.  Diagnosis and classification of multiple sclerosis.

Authors:  W I McDonald; A M Halliday
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

8.  Bolus methylprednisolone in severe aplastic anemia.

Authors:  A Bacigalupo; D Giordano; M T Van Lint; R Vimercati; A M Marmont
Journal:  N Engl J Med       Date:  1979-03-01       Impact factor: 91.245

9.  Effect of corticosteroids on the human immune response. Suppression of mitogen-induced lymphocyte proliferation by "pulse" methylprednisolone.

Authors:  P T Fan; D T Yu; C Targoff; R Bluestone
Journal:  Transplantation       Date:  1978-10       Impact factor: 4.939

10.  Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis.

Authors:  P C Dowling; V V Bosch; S D Cook
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

View more
  9 in total

1.  Immunological treatment of multiple sclerosis. II.

Authors:  R A Hughes
Journal:  J Neurol       Date:  1986-04       Impact factor: 4.849

2.  Methylprednisolone in multiple sclerosis: a comparative dose study.

Authors:  L Bindoff; P R Lyons; P K Newman; M Saunders
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-08       Impact factor: 10.154

Review 3.  Immunotherapy for multiple sclerosis.

Authors:  R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

Review 4.  Current pharmacologic treatment of multiple sclerosis symptoms.

Authors:  P B Andersson; D E Goodkin
Journal:  West J Med       Date:  1996-11

Review 5.  Treatment of acute relapses in multiple sclerosis.

Authors:  Regina Berkovich
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 6.  Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.

Authors:  Stacey Murray; Andrew Woo
Journal:  Ther Adv Neurol Disord       Date:  2015-12-07       Impact factor: 6.570

7.  Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.

Authors:  S M Alam; T Kyriakides; M Lawden; P K Newman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

8.  Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses.

Authors:  Ola Caster; I Ralph Edwards
Journal:  BMC Neurol       Date:  2015-10-16       Impact factor: 2.474

9.  Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population.

Authors:  Tara Nazareth; Manasi Datar; Tzy-Chyi Yu
Journal:  Neurol Ther       Date:  2019-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.